|
|
|
Strategic Research Institute, Park Hyatt at the Bellevue
June 21-22, 2004
Speakers scheduled include selected gusts from The Genomics Institute of the Novartis Foundation, Celgene, The National Cancer Institute at Frederick and Harvard University.
|
|
|
|
|
|
Organized by:
|
|
Strategic Research Institute |
|
Invited Speakers:
|
|
With the recent clinical validation of VELCADE, the first proteasome inhibitor to be approved by the FDA for cancer therapy, interest has exploded in the ubiquitin-proteasome pathway field. In addition to cancer, research is under way for the potential of therapeutic intervention in many other disease areas such as antiviral, osteoporosis and muscular atrophy. By attending this conference, you will hear from leading industrial and academic experts and take away the latest research in the field.
|
|
|
|
|
|
Deadline for Abstracts:
|
|
June 1. 2004
|
|
|
|
|
|
Registration:
|
|
Register by April 30 for a special early bird rate
|
|
E-mail:
|
|
info@srinstitue.com
|
|
|
|
|
|
|
|